NO20063108L - Stabiliserte, flytende interferonformuleringer - Google Patents

Stabiliserte, flytende interferonformuleringer

Info

Publication number
NO20063108L
NO20063108L NO20063108A NO20063108A NO20063108L NO 20063108 L NO20063108 L NO 20063108L NO 20063108 A NO20063108 A NO 20063108A NO 20063108 A NO20063108 A NO 20063108A NO 20063108 L NO20063108 L NO 20063108L
Authority
NO
Norway
Prior art keywords
interferon
formulations
stabilized liquid
cyclodextrin
room temperature
Prior art date
Application number
NO20063108A
Other languages
English (en)
Inventor
Maria Dorly Del Curto
Original Assignee
Ares Trading Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ares Trading Sa filed Critical Ares Trading Sa
Publication of NO20063108L publication Critical patent/NO20063108L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/215—IFN-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Inorganic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

Stabilisert flytende farmasøytisk sammensetning som omfatter et interferon (IFN) eller en isoform, mutein, fusjonert protein, funksjonelt derivat, aktiv fraksjon eller et salt derav, hvori nevnte formulering er en oppløsning som omfatter en buffer, et syklodekstrin, et isotonisitetsmiddel og et antioksiderende middel er beskrevet heri. Fortrinnsvis er interferonet interferon beta-la og syklodekstrinet er HPBCD. Disse formuleringer er stabile ved romtemperatur og bibringer således den fordel at omkostningene for formuleringslagring er mindre og øker sikkerheten for pasienten med hensyn til mulige "feil" under behandling. Faktum er at å ha slike formuleringer stabile ved romtemperatur reduser er risikoen for dannelse av degraderingsprodukter som eventuelt kan være ansvarlig for uheldige hendelser (for eksempel immunogenisitet).
NO20063108A 2003-12-11 2006-07-04 Stabiliserte, flytende interferonformuleringer NO20063108L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP03104646 2003-12-11
EP04103349 2004-07-13
PCT/EP2004/053407 WO2005058346A1 (en) 2003-12-11 2004-12-10 Stabilized interferon liquid formulations

Publications (1)

Publication Number Publication Date
NO20063108L true NO20063108L (no) 2006-07-04

Family

ID=34702349

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20063108A NO20063108L (no) 2003-12-11 2006-07-04 Stabiliserte, flytende interferonformuleringer

Country Status (18)

Country Link
US (1) US7846427B2 (no)
EP (1) EP1691825B1 (no)
JP (1) JP4658961B2 (no)
AT (1) ATE526032T1 (no)
AU (1) AU2004298781B2 (no)
BR (1) BRPI0416980A (no)
CA (1) CA2547822A1 (no)
CY (1) CY1112193T1 (no)
DK (1) DK1691825T3 (no)
ES (1) ES2374530T3 (no)
HR (1) HRP20110699T1 (no)
IL (1) IL176021A0 (no)
NO (1) NO20063108L (no)
PL (1) PL1691825T3 (no)
PT (1) PT1691825E (no)
RS (1) RS52218B (no)
SI (1) SI1691825T1 (no)
WO (1) WO2005058346A1 (no)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI272948B (en) * 2003-05-01 2007-02-11 Ares Trading Sa HSA-free stabilized interferon liquid formulations
EA012205B1 (ru) * 2004-05-17 2009-08-28 Арес Трейдинг С.А. Гидрогелевые препараты интерферона
WO2008137471A2 (en) 2007-05-02 2008-11-13 Ambrx, Inc. Modified interferon beta polypeptides and their uses
US7951368B2 (en) 2007-06-25 2011-05-31 Amgen Inc. Compositions of specific binding agents to hepatocyte growth factor
CA2707840A1 (en) 2007-08-20 2009-02-26 Allozyne, Inc. Amino acid substituted molecules
PT2234645E (pt) * 2007-12-20 2012-05-21 Merck Serono Sa Formulações de peg-interferão-beta
US20100203014A1 (en) * 2009-02-04 2010-08-12 Aegis Therapeutics Llc Zwitterionic buffered acidic peptide and protein formulations
KR20150074167A (ko) 2012-10-26 2015-07-01 루핀 리미티드 Ｐｅｇ 인터페론 알파-2ｂ의 안정한 약학 조성물
GB201604124D0 (en) * 2016-03-10 2016-04-27 Ucb Biopharma Sprl Pharmaceutical formulation
EP3687498A1 (en) 2017-09-27 2020-08-05 Novartis AG Parenteral formulation comprising siponimod
CN111494611A (zh) * 2020-06-08 2020-08-07 长春生物制品研究所有限责任公司 一种卡式瓶多剂量笔式注射组合包装的干扰素注射液
CN113797317B (zh) * 2021-10-26 2024-01-09 科兴生物制药股份有限公司 一种组合物及其制备方法和应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5997856A (en) * 1988-10-05 1999-12-07 Chiron Corporation Method and compositions for solubilization and stabilization of polypeptides, especially proteins
US6582728B1 (en) 1992-07-08 2003-06-24 Inhale Therapeutic Systems, Inc. Spray drying of macromolecules to produce inhaleable dry powders
US5814485A (en) * 1995-06-06 1998-09-29 Chiron Corporation Production of interferon-β (IFN-β) in E. coli
ZA9610374B (en) * 1995-12-11 1997-06-23 Elan Med Tech Cartridge-based drug delivery device
EP1037995A1 (en) * 1997-12-08 2000-09-27 Genentech, Inc. Human interferon-epsilon: a type 1 interferon
US6887462B2 (en) * 2001-04-09 2005-05-03 Chiron Corporation HSA-free formulations of interferon-beta
JP2004522803A (ja) * 2001-06-29 2004-07-29 マキシゲン・エイピーエス インターフェロン製剤
TWI272948B (en) 2003-05-01 2007-02-11 Ares Trading Sa HSA-free stabilized interferon liquid formulations
EA012205B1 (ru) 2004-05-17 2009-08-28 Арес Трейдинг С.А. Гидрогелевые препараты интерферона
CN1993139B (zh) 2004-06-01 2011-02-16 阿雷斯贸易股份有限公司 稳定的干扰素液体制剂

Also Published As

Publication number Publication date
US20070104682A1 (en) 2007-05-10
AU2004298781B2 (en) 2010-04-01
DK1691825T3 (da) 2011-12-05
ES2374530T3 (es) 2012-02-17
HRP20110699T1 (hr) 2011-10-31
JP4658961B2 (ja) 2011-03-23
IL176021A0 (en) 2006-10-05
JP2007513925A (ja) 2007-05-31
RS52218B (en) 2012-10-31
ATE526032T1 (de) 2011-10-15
WO2005058346A1 (en) 2005-06-30
US7846427B2 (en) 2010-12-07
BRPI0416980A (pt) 2007-02-21
EP1691825B1 (en) 2011-09-28
CY1112193T1 (el) 2015-12-09
PT1691825E (pt) 2011-10-12
PL1691825T3 (pl) 2012-02-29
SI1691825T1 (sl) 2011-12-30
EP1691825A1 (en) 2006-08-23
CA2547822A1 (en) 2005-06-30
AU2004298781A1 (en) 2005-06-30

Similar Documents

Publication Publication Date Title
NO20063108L (no) Stabiliserte, flytende interferonformuleringer
ES2418833T3 (es) Formulaciones líquidas de interferón estabilizadas
DE502004012418D1 (de) Formulierung für proteinarzneimittel ohne zusatz von humanem serumalbumin (hsa)
CY1115233T1 (el) Υγρα σταθεροποιημενα σκευασματα ιντερφερονης-βητα σε επικαλυμμενους περιεκτες φαρμακευτικης χρησης
KR970706017A (ko) 안정한 알파 인터페론 수용액 제형(Stable, aqueous alfainterfer on solution for mulations)
NO953278L (no) Fremgangsmåter for in vivo-levering av biologisk aktive stoffer og sammensetninger som er nyttige for dette
BRPI0410488B8 (pt) Composição farmacêutica líquida estabilizada e livre de hsa, método para preparação de composição farmacêutica líquida estabilizada e livre de hsa, e recipiente vedado hermeticamente
UY25055A1 (es) Formulaciones farmacéuticas que contienen voriconazol
NO20054440L (no) Flytende formuleringer av tumornekrosefaktorbindende proteiner
CA2304808A1 (en) Liquid interferon-.beta. formulations
DK0722313T3 (da) Viskoelastiske sammensætninger af fluorerede organiske forbindelser
DK1044015T3 (da) Formuleringer med amylinagonistpeptider og insulin
HUP0302311A2 (hu) Gyógyászati aeroszol-készítmények
ATE275974T1 (de) Zusammensetzungen enthaltend glykolderivate, alkohole und vitamin d
ATE359777T1 (de) Fenofibratsäure enthaltende pharmazeutische zusammensetzung und deren physiologisch verträgliche salze und derivate
AR017066A1 (es) Cristales de glicoproteina, de enlazamiento cruzado con carbohidrato
JP4871720B2 (ja) 血清アルブミンを含まない、安定なヒトエリスロポエチン水溶液
KR101699677B1 (ko) 고나도트로핀을 위한 제제
CO4830457A1 (es) Preparados efervescentes
JP2008050320A (ja) インターフェロン−β含有医薬組成物
DE60134883D1 (de) Interferon- und interleukin-derivate mit langzeitwirkung und diese enthaltende pharmazeutische zusammensetzungen
CA2486571A1 (en) Pharmaceutical composition
BR0215498A (pt) Composição farmacêutica compreendendo uma glitazona e um ácido 4-oxobutanóico e o seu uso para o tratamento de diabetes

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application